The latest news from the global pharmaceutical industry. Below you will find news and information to keep you up-to-date with what is happening in your industry. Coverage includes regulatory approvals, recall announcements, mergers and acquisitions, personnel news and appointments, new facility and facility expansion updates, collaborations and agreements, and financial updates.
BioAtla announced the FDA has cleared BioAtla's IND for BA3021, a first-in-class conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-...
read more
Alkermes announced that the FDA has accepted for review the NDA for ALKS 5461, a novel, once-daily, oral investigational medicine for the adjunctive ...
read more
NGM Bio announced data from a Phase 2 study of its lead product candidate, NGM282, demonstrating clinically meaningful improvements in histological ...
read more
Apitope announced positive results from the Phase I first in man clinical trial of its product candidate, ATX-GD-59, in development for the treatment ...
read more
Kalytera Therapeutics announced the termination of its pre-clinical development programs in the treatment of bone disease.
read more
Pfizer has initiated a Phase 1b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926, in boys with Duchenne muscular dystrophy.
read more
Wednesday, April 11, 2018
BiondVax reported the first participant enrollment in the United States in a Phase 2 clinical trial of the company's universal flu vaccine candidate, ...
read more
Wednesday, April 11, 2018
Fujifilm Kyowa Kirin Biologics announced the company will partner with Mylan to commercialize FKB327, a biosimilar to Humira developed by Fujifilm ...
read more
Based on the FDA’s guidance, Kadmon plans to initiate an open-label, two-arm, pivotal Phase 2 clinical trial to support the potential registration of ...
read more
RegeneRx announced the outcome of discussions between ReGenTree and the FDA regarding the results of the completed clinical trial and the future ...
read more
AbbVie announced positive top-line results from the Phase 3 clinical trial showing that after 12 weeks, upadacitinib met the primary endpoints of ...
read more
Incyte and Merck announced a review of the study results evaluating Incyte’s epacadostat in combination with KEYTRUDA did not meet the primary ...
read more
FORMA Therapeutics has successfully completed a critical objective under its strategic collaboration agreement with Celgene, triggering an undisclosed...
read more
QurAlis announced the addition of biotech investors MPH, Amgen Ventures, and Alexandria Venture Investments, who have joined to cure Amyotrophic ...
read more
Wednesday, April 04, 2018
Eli Lilly and Company announced top-line results from its Phase 3 REACH-2 study of CYRAMZA as a single agent in the second-line treatment of people ...
read more